3,6'-Dithiopomalidomide reduces neural loss, inflammation, behavioral deficits in brain injury and microglial activation

  1. Chih-Tung Lin
  2. Daniela Lecca
  3. Ling-Yu Yang
  4. Weiming Luo
  5. Michael T Scerba
  6. David Tweedie
  7. Pen-Sen Huang
  8. Yoo-Jin Jung
  9. Dong Seok Kim
  10. Chih-Hao Yang
  11. Barry J Hoffer
  12. Jia-Yi Wang  Is a corresponding author
  13. Nigel H Greig  Is a corresponding author
  1. Taipei Medical University, Taiwan
  2. National Institute on Aging, NIH, United States
  3. Case Western Reserve University, United States

Abstract

Traumatic brain injury (TBI) causes mortality and disability worldwide. It can initiate acute cell death followed by secondary injury induced by microglial activation, oxidative stress, inflammation and autophagy in brain tissue, resulting in cognitive and behavioral deficits. We evaluated a new pomalidomide (Pom) analog, 3,6'-dithioPom (DP), and Pom as immunomodulatory agents to mitigate TBI-induced cell death, neuroinflammation, astrogliosis and behavioral impairments in rats challenged with controlled cortical impact TBI. Both agents significantly reduced the injury contusion volume and degenerating neuron number evaluated histochemically and by MRI at 24 hr and 7 days, with a therapeutic window of 5 hr post-injury. TBI-induced upregulated markers of microglial activation, astrogliosis and the expression of proinflammatory cytokines, iNOS, COX-2, and autophagy-associated proteins were suppressed, leading to an amelioration of behavioral deficits with DP providing greater potency. Complementary animal and cellular studies demonstrated DP and Pom mediated reductions in markers of neuroinflammation and a-synuclein-induced toxicity.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for all figures.

Article and author information

Author details

  1. Chih-Tung Lin

    Graduate Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan
    Competing interests
    No competing interests declared.
  2. Daniela Lecca

    Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, United States
    Competing interests
    No competing interests declared.
  3. Ling-Yu Yang

    Graduate Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan
    Competing interests
    No competing interests declared.
  4. Weiming Luo

    Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, United States
    Competing interests
    Weiming Luo, NHG, WL and DT are named inventors on patent 8,927,725 and have assigned all their rights to the NIH (US Government), and hence have noownership of DP or other agents within US Patent 8,927,725..
  5. Michael T Scerba

    Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, United States
    Competing interests
    No competing interests declared.
  6. David Tweedie

    Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, United States
    Competing interests
    David Tweedie, NHG, WL and DT are named inventors on patent 8,927,725 and have assigned all their rights to the NIH (US Government), and hence have noownership of DP or other agents within US Patent 8,927,725..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8446-4544
  7. Pen-Sen Huang

    Graduate Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan
    Competing interests
    No competing interests declared.
  8. Yoo-Jin Jung

    Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, United States
    Competing interests
    No competing interests declared.
  9. Dong Seok Kim

    Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, United States
    Competing interests
    No competing interests declared.
  10. Chih-Hao Yang

    Department of Pharmacology, School of Medicine, College of Medicine,, Taipei Medical University, Taipei, Taiwan
    Competing interests
    No competing interests declared.
  11. Barry J Hoffer

    Department of Neurological Surgery, Case Western Reserve University, Cleveland, United States
    Competing interests
    No competing interests declared.
  12. Jia-Yi Wang

    Dept. Neurosurgery & Neuroscience Research Center, Taipei Medical University, Taipei, Taiwan
    For correspondence
    jywang2010@tmu.edu.tw
    Competing interests
    No competing interests declared.
  13. Nigel H Greig

    Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, United States
    For correspondence
    Greign@grc.nia.nih.gov
    Competing interests
    Nigel H Greig, NHG, WL and DT are named inventors on patent 8,927,725 and have assigned all their rights to the NIH (US Government), and hence have no ownership of DP or other agents within US Patent 8,927,725..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3032-1468

Funding

National Institutes of Health, NIA, Intramural Research Program (AG000994)

  • Nigel H Greig

National Institutes of Health (AG057025 (R56))

  • Barry J Hoffer

Ministry of Science and Technology, Taiwan (MOST 104-2923-B-038-001-MY3)

  • Jia-Yi Wang

Ministry of Science and Technology, Taiwan (MOST 108-2321-B-038-008)

  • Jia-Yi Wang

Taipei Medical University (DP2-107-21121-01-N-05)

  • Jia-Yi Wang

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Sonia Garel, Ecole Normale Superieure, France

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All animals were treated according to the International Guidelines for animal research, and the animal use protocols in this study were reviewed and approved by the Institutional Animal Care and Use Committee or Panel (IACUC/IACUP) of either the Intramural Research Program, National Institute on Aging, NIH (protocol No. 331-TGB-2021), or of Taipei Medical University [Protocol number: LAC-2015-0051]. All surgery was performed under appropriate anesthesia, and every effort was made to minimize suffering.

Version history

  1. Received: December 24, 2019
  2. Accepted: June 12, 2020
  3. Accepted Manuscript published: June 26, 2020 (version 1)
  4. Version of Record published: July 22, 2020 (version 2)

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 2,070
    Page views
  • 313
    Downloads
  • 22
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Chih-Tung Lin
  2. Daniela Lecca
  3. Ling-Yu Yang
  4. Weiming Luo
  5. Michael T Scerba
  6. David Tweedie
  7. Pen-Sen Huang
  8. Yoo-Jin Jung
  9. Dong Seok Kim
  10. Chih-Hao Yang
  11. Barry J Hoffer
  12. Jia-Yi Wang
  13. Nigel H Greig
(2020)
3,6'-Dithiopomalidomide reduces neural loss, inflammation, behavioral deficits in brain injury and microglial activation
eLife 9:e54726.
https://doi.org/10.7554/eLife.54726

Share this article

https://doi.org/10.7554/eLife.54726

Further reading

    1. Neuroscience
    Kiwamu Kudo, Kamalini G Ranasinghe ... Srikantan S Nagarajan
    Research Article

    Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-β and misfolded tau proteins causing synaptic dysfunction, and progressive neurodegeneration and cognitive decline. Altered neural oscillations have been consistently demonstrated in AD. However, the trajectories of abnormal neural oscillations in AD progression and their relationship to neurodegeneration and cognitive decline are unknown. Here, we deployed robust event-based sequencing models (EBMs) to investigate the trajectories of long-range and local neural synchrony across AD stages, estimated from resting-state magnetoencephalography. The increases in neural synchrony in the delta-theta band and the decreases in the alpha and beta bands showed progressive changes throughout the stages of the EBM. Decreases in alpha and beta band synchrony preceded both neurodegeneration and cognitive decline, indicating that frequency-specific neuronal synchrony abnormalities are early manifestations of AD pathophysiology. The long-range synchrony effects were greater than the local synchrony, indicating a greater sensitivity of connectivity metrics involving multiple regions of the brain. These results demonstrate the evolution of functional neuronal deficits along the sequence of AD progression.

    1. Medicine
    2. Neuroscience
    Luisa Fassi, Shachar Hochman ... Roi Cohen Kadosh
    Research Article

    In recent years, there has been debate about the effectiveness of treatments from different fields, such as neurostimulation, neurofeedback, brain training, and pharmacotherapy. This debate has been fuelled by contradictory and nuanced experimental findings. Notably, the effectiveness of a given treatment is commonly evaluated by comparing the effect of the active treatment versus the placebo on human health and/or behaviour. However, this approach neglects the individual’s subjective experience of the type of treatment she or he received in establishing treatment efficacy. Here, we show that individual differences in subjective treatment - the thought of receiving the active or placebo condition during an experiment - can explain variability in outcomes better than the actual treatment. We analysed four independent datasets (N = 387 participants), including clinical patients and healthy adults from different age groups who were exposed to different neurostimulation treatments (transcranial magnetic stimulation: Studies 1 and 2; transcranial direct current stimulation: Studies 3 and 4). Our findings show that the inclusion of subjective treatment can provide a better model fit either alone or in interaction with objective treatment (defined as the condition to which participants are assigned in the experiment). These results demonstrate the significant contribution of subjective experience in explaining the variability of clinical, cognitive, and behavioural outcomes. We advocate for existing and future studies in clinical and non-clinical research to start accounting for participants’ subjective beliefs and their interplay with objective treatment when assessing the efficacy of treatments. This approach will be crucial in providing a more accurate estimation of the treatment effect and its source, allowing the development of effective and reproducible interventions.